ES2181602B1 - "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral. - Google Patents

"complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.

Info

Publication number
ES2181602B1
ES2181602B1 ES200101784A ES200101784A ES2181602B1 ES 2181602 B1 ES2181602 B1 ES 2181602B1 ES 200101784 A ES200101784 A ES 200101784A ES 200101784 A ES200101784 A ES 200101784A ES 2181602 B1 ES2181602 B1 ES 2181602B1
Authority
ES
Spain
Prior art keywords
isopropylamine
dimethylamine
trans
complex
applicable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200101784A
Other languages
English (en)
Other versions
ES2181602A1 (es
Inventor
Carmen Navarro Ranninger
Eva I. Montero Veliz
Jose Manuel Perez Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Priority to ES200101784A priority Critical patent/ES2181602B1/es
Priority to PCT/ES2002/000383 priority patent/WO2003033511A1/es
Publication of ES2181602A1 publication Critical patent/ES2181602A1/es
Application granted granted Critical
Publication of ES2181602B1 publication Critical patent/ES2181602B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Complejo de Pt(IV) con actividad antineoplástica: trans- (PtC1{sub,2}(OH){sub,2} (dimetilamina) (isopropilamina)) aplicable como antitumoral, consiste en un complejo de Pt(IV) trans-(PtC1{sub,2}(OH){sub,2} (dimetilamina) (isopropilamina).
ES200101784A 2001-07-30 2001-07-30 "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral. Expired - Fee Related ES2181602B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200101784A ES2181602B1 (es) 2001-07-30 2001-07-30 "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.
PCT/ES2002/000383 WO2003033511A1 (es) 2001-07-30 2002-07-30 COMPLEJO DE Pt(IV) CON ACTIVIDAD ANTINEOPLÁSICA: TRANS-[PtCl2(OH)2 (DIMETILAMINA) (ISOPROPILAMINA)] APLICABLE COMO ANTITUMORAL

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101784A ES2181602B1 (es) 2001-07-30 2001-07-30 "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.

Publications (2)

Publication Number Publication Date
ES2181602A1 ES2181602A1 (es) 2003-02-16
ES2181602B1 true ES2181602B1 (es) 2004-06-16

Family

ID=8498565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200101784A Expired - Fee Related ES2181602B1 (es) 2001-07-30 2001-07-30 "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.

Country Status (2)

Country Link
ES (1) ES2181602B1 (es)
WO (1) WO2003033511A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214138B1 (es) * 2003-02-21 2005-10-16 Universidad Autonoma De Madrid Compuestos trans de platino (iv) de formula trans, trans, trans - (ptcl2 (oh)2 (amina) (dimetilamina)) con actividad antitumoral.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1578323A (en) * 1976-02-26 1980-11-05 Rustenburg Platinum Mines Ltd Compositions containing platinum
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELLAND, LLOYD R. y col. Synthesis and in vitro and in vivo antitumor activity of a series of trans Platinum antitumor complexes. Journal of Medicinal Chemistry, 1995, Vol. 38, Nº 16, páginas 3016-3024, ISSN 0022-2623. Todo el documento. *
MONTERO, E.I. y col. Preparation and characterization of novel trans [PtCl2(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in rats-transformed cells. J. Med. Chem., 7 Octubre 1999, Vol. 42, Nº 20, páginas 4264-4268. Todo el documento. *
REIKO KURODA y col. X-Ray and NMR studies of Trans-dihydroxo-platinum (IV) antitumor complexes. J. Inorg. Biochem., 1984, Vol. 22, Nº 3, páginas 103-177, ISSN 0162-0134. Todo el documento. *

Also Published As

Publication number Publication date
ES2181602A1 (es) 2003-02-16
WO2003033511A1 (es) 2003-04-24

Similar Documents

Publication Publication Date Title
ATE546109T1 (de) Mehrlumige prothesensysteme
TR200102856T1 (tr) Antitümör ajanları olarak C7 ester ikameli taksanlar.
TW200636462A (en) Operating system-independent memory power management
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
AU2003267730A1 (en) Integrated circuit and method for establishing transactions
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
DE602006002301D1 (de) Drehbarer Sitz
EP1909403A3 (en) Frequency hopping design for IFDMA, LFDMA and OFDMA systems
ATE245655T1 (de) Organische-arsenverbindungen
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
ES2181602B1 (es) "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.
ZA200303986B (en) Coherent jet system with single ring flame envelope.
DE60227244D1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
ATE208774T1 (de) Arylsulfonylimidazolon-derivate als antitumormittel
AU7113600A (en) High-availability, shared-memory cluster
NO20014758L (no) C(7)-heterosubstituerte acetattaxaner som antitumormidler
BR0104779A (pt) Taxanos substituìdos com carbonato c10 comoagentes antitumor
DK1117393T3 (da) L-acetylcarnitin som antitumorpræparat
GB2431406A (en) Light-emitting device comprising metal complexes with biphosphinine ligandas
IT1312358B1 (it) Addotto della vitamina k,particolarmente idoneo come integratorevitaminico per mangimi
NO20014754D0 (no) C(10)-estersubstituerte taksaner som antitumormidler
NO20014757D0 (no) C(7)-karbamoyloksysubstituerte taksaner som antitumormidler
AU2002336020A1 (en) Antiagionecic, antitumor, chemopreventative agents
CN213237352U (zh) 一种工具灯定制cob光源
DK1436278T3 (da) Fremgangsmåde til fremstilling af 14-beta-hydroxy-baccatin-III-1,14-carbonat

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030216

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2181602B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211108